Alchemab Therapeutics vs CellCentric
Alchemab Therapeutics vs CellCentric, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Alchemab Therapeutics is on 42/100 and CellCentric on 60/100.
Where each one leads
Alchemab Therapeutics
- agent readiness: 36/100 against 32/100
CellCentric
- our overall score: 60/100 against 42/100
- funding raised: $375M against $31.5M
At a glance
| Measure | Alchemab Therapeutics | CellCentric |
|---|---|---|
| What it is | Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals. | A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma. |
| Category | Biotechnology, Pharmaceuticals, Artificial Intelligence, Drug Discovery | Biotechnology, Pharmaceuticals, Healthcare, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2019 | 2003 |
| Headquarters | London, United Kingdom | Cambridge, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | Alchemab Therapeutics | CellCentric |
|---|---|---|
| Employees | Not published | 53 |
| Total funding | $31.5M | $375M |
| Latest round | Series A | Series D |
| LinkedIn followers | Not published | 28,695 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Alchemab Therapeutics | CellCentric |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 42/100 | 60/100 |
| Traction | 37/100 | 57/100 |
| Team | Not published | 60/100 |
| Search visibility | 8/100 | 44/100 |
| Quality | 58/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (36/100) | F (32/100) |
| Domain ratingLink authority, 0-100 | 33/100 | 35/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Alchemab Therapeutics | CellCentric |
|---|---|---|
| Hosting | Google Cloud | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery |
| Analytics | Google Analytics 4 | Google Analytics 4 |
Alchemab Therapeutics vs CellCentric: common questions
Which is better, Alchemab Therapeutics or CellCentric?
On our 0-100 score CellCentric rates higher (60/100 against 42/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Alchemab Therapeutics and CellCentric compare on the numbers?
Alchemab Therapeutics leads on agent readiness (36/100 against 32/100). CellCentric leads on our overall score (60/100 against 42/100), funding raised ($375M against $31.5M).
Read the full Alchemab Therapeutics review and pricing or the CellCentric review and pricing. You can also browse other Alchemab Therapeutics alternatives we track.